NCT07612878Recruiting
The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry
Source: ClinicalTrials.gov · Last updated 15 Oct 2026
Brief summary (registry, in English)
The STRIDE Registry will evaluate the real-world effectiveness and safety of dupilumab in participants with COPD. The primary objective is to describe characteristics of participants newly initiated with dupilumab for COPD. Secondary objectives are to determine whether treatment with dupilumab reduces moderate and/or severe COPD exacerbations; to determine the impact of treatment on lung function in COPD participants; to determine whether treatment with dupilumab improves the quality of life in COPD participants; and to describe safety of dupilumab among COPD participants. The external control cohort will include participants with COPD from the National Patient-Centered Clinical Research Network (PCORnet) consortium who are not being treated with dupilumab. In addition, chest images will be collected and banked for future research projects and consented participants will perform home spirometry.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 350 (estimated)
- First submitted
- 19 May 2026
- Start date
- 6 Aug 2026
- Primary completion date
- 30 Jun 2029
- Lead sponsor
- Sanofi
- Diseases
- COPD
- NCT number
- NCT07612878
What you commit to
- Study type: Observational
- Planned participants: 350
- From 6 Aug 2026 to the primary completion date, 30 Jun 2029
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any condition that, in the opinion of the Investigator, may interfere with the patient's ability to participate in the study, such as short life expectancy, or other comorbidities that can predictably prevent the patient from completing the schedule of assessments
Other
- Patients who have contraindication to dupilumab according to the United States Prescribing Information (USPI)
- Patients currently participating in any interventional clinical trial The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
Who the study is looking for
- COPD patients who are newly referred to start dupilumab treatment
- Age ≥ 40 years
- Standard of care spirometry performed concurrently with the baseline visit or within 90 days prior to the baseline visit
Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ohio State University Coordinator of this site? Confirm its status | Columbus | United States | Recruiting |
| Duke Coordinator of this site? Confirm its status | Durham | United States | Recruiting |
| The Respire Institute Coordinator of this site? Confirm its status | Houston | United States | Recruiting |
| IU Health Pulmonology & Critical Care Medicine Coordinator of this site? Confirm its status | Indianapolis | United States | Recruiting |
| Activian Clinical Research Coordinator of this site? Confirm its status | Kingwood | United States | Recruiting |
| University of Kansas Coordinator of this site? Confirm its status | Lawrence | United States | Recruiting |
| The Lung & Sleep Institute of North Texas Coordinator of this site? Confirm its status | North Richland Hills | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.